Patents by Inventor Daniel Custar

Daniel Custar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210347779
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: January 5, 2021
    Publication date: November 11, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun ZHENG, Xiaojie ZHU, Hong DU, Maarten POSTEMA, Yimin JIANG, Jing LI, Robert YU, Hyeong-Wook CHOI, Jaemoon LEE, Francis G. FANG, Daniel CUSTAR
  • Patent number: 10941148
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20190315754
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 17, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Patent number: 10316040
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 11, 2019
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20180305362
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar